Acquired resistance of Escherichia coli to complement lysis by binding of glycophosphoinositol-anchored protectin (CD59). - Wikidata - wikimedia - TriplyDB

Acquired resistance of Escherichia coli to complement lysis by binding of glycophosphoinositol-anchored protectin (CD59).

Acquired resistance of Escherichia coli to complement lysis by binding of glycophosphoinositol-anchored protectin (CD59).

http://www.wikidata.org/entity/Q33753497

about

Biomedical applications of glycosylphosphatidylinositol-anchored proteins Complement evasion by human pathogens.The Vsa proteins modulate susceptibility of Mycoplasma pulmonis to complement killing, hemadsorption, and adherence to polystyrene.Protease-dependent mechanisms of complement evasion by bacterial pathogens.BrkA protein of Bordetella pertussis inhibits the classical pathway of complement after C1 deposition.Binding of vitronectin by the Moraxella catarrhalis UspA2 protein interferes with late stages of the complement cascade.Oral Campylobacter species: Initiators of a subgroup of inflammatory bowel disease?The Functional Amyloid Curli Protects Escherichia coli against Complement-Mediated Bactericidal Activity.

P2860

Q27468625-C109298F-9440-414D-9116-59160C4C9CAA Q33623972-CBCC8290-3D3B-461C-B057-1EB098B789F0 Q36046082-68BF2371-C554-4535-85D1-1BBE6EDD6AC6 Q36368916-4FEBA5AE-C354-4D0C-8F5C-23C65141AE2A Q39519868-3DEC8CAE-D9A5-4FE7-AE18-AF5BBBB2FF44 Q40312702-4B07A9EB-BF22-47E4-BCF5-6384864106A6 Q42618712-35387FB5-D864-43EA-A64C-18C5B6CB1088 Q48174563-F6E5F4A9-64D7-400E-AD45-B49AA370B4C9

P2860

Acquired resistance of Escherichia coli to complement lysis by binding of glycophosphoinositol-anchored protectin (CD59).

http://www.wikidata.org/entity/Q33753497

description

1998 nî lūn-bûn

@nan

1998 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

1998 թվականի մայիսին հրատարակված գիտական հոդված

@hy

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

name

Acquired resistance of Escheri ...... tol-anchored protectin (CD59).

@ast

Acquired resistance of Escheri ...... tol-anchored protectin (CD59).

@en

type

label

Acquired resistance of Escheri ...... tol-anchored protectin (CD59).

@ast

Acquired resistance of Escheri ...... tol-anchored protectin (CD59).

@en

prefLabel

Acquired resistance of Escheri ...... tol-anchored protectin (CD59).

@ast

Acquired resistance of Escheri ...... tol-anchored protectin (CD59).

@en

P1433

Q33753497-87CADA22-12A7-4E7E-B8CF-375246D53E47

P1476

Q33753497-B159F1A5-1D19-4200-AD73-20A23333D8A4

P2093

Q33753497-690FF8E7-81D0-4645-A824-8CE7B3EDC1A4

Q33753497-A3220702-6910-4B33-98CC-B1E01BB69FE8

Q33753497-D1855533-EA04-42A9-862A-78F3E87F39A0

Q33753497-F92F362C-4132-4080-BE4E-4BE0ECD8A883

P2860

Q33753497-0105213A-D41B-40A6-94FF-A4151B6B92DC

Q33753497-018A6271-88FB-4C08-93DB-D43816CEDBA0

Q33753497-1056A46C-4613-41B1-ABB1-D3C42109394C

Q33753497-24B64093-5F68-4801-B476-43491CD45E23

Q33753497-254441F7-CE9E-45AE-9A53-625565C19593

Q33753497-3152D16B-1A2F-4E4C-9317-04606C6999D6

Q33753497-331C36B1-1A41-4AE3-B598-D14CD7CA1547

Q33753497-33A7BA55-41EF-4BE2-BC7A-C0C654746ABD

Q33753497-359F1FB9-F8FD-4E74-A9E7-189EDF9AC042

Q33753497-57C5A7FD-BEC5-4BBB-8305-5B91F40A967B

P304

Q33753497-A1BC1419-8796-4C74-8664-EDD7D1535B2F

P31

Q33753497-420CAF56-8778-41D7-BF60-4DBAAC4A27AA

P407

Q33753497-E2D2A788-2F59-4A83-BF57-D8BC1E92CC2A

P433

Q33753497-85B462D8-6366-4D77-8C18-821BA30AD642

P478

Q33753497-A4281E4A-669B-413F-A49E-04DF14435DDD

P577

Q33753497-C415C086-11D9-49B5-AEB7-6AA722532C21

P698

Q33753497-FC461986-4B43-4EE9-96DF-9254356D4969

P932

Q33753497-68FD94E1-5331-4D9B-8997-48E4868E813B

P1433

Infection and Immunity

P1476

Acquired resistance of Escheri ...... tol-anchored protectin (CD59).

@en

P2093

G A Jarvis

http://www.w3.org/2001/XMLSchema#string

P Marnila

http://www.w3.org/2001/XMLSchema#string

R Rautemaa

http://www.w3.org/2001/XMLSchema#string

S Meri

http://www.w3.org/2001/XMLSchema#string

P2860

CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells

Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3

Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8

Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H.

Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H.

Elastase of Pseudomonas aeruginosa: inactivation of complement components and complement-derived chemotactic and phagocytic factors.

Studies on the mechanism of bacterial resistance to complement-mediated killing. II. C8 and C9 release C5b67 from the surface of Salmonella minnesota S218 because the terminal complex does not insert into the bacterial outer membrane.

Studies on the mechanism of bacterial resistance to complement-mediated killing. I. Terminal complement components are deposited and released from Salmonella minnesota S218 without causing bacterial death.

Outer membrane of Salmonella typhimurium: chemical analysis and freeze-fracture studies with lipopolysaccharide mutants.

Characterization of lipopolysaccharides from Escherichia coli K-12 mutants.

P304

1928-1933

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P577

1998-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9573071

http://www.w3.org/2001/XMLSchema#string

P932

108145

http://www.w3.org/2001/XMLSchema#string